Acarix A/S was established in 2009 as a spinout from Coloplast A/S. Since 2010 key investors SEED Capital Denmark and Sunstone Life Science Ventures have financed the company and supported it towards market introduction. Acarix is a medical device company specializing in non-invasive, non-radiation acoustic detection of Coronary Artery Disease (CAD).
A recent Danish study showed that more than 90% of patients presenting Coronary Artery Disease (CAD) symptoms to their general practitioner do not have CAD. With the Acarix CADScor®System we have an easy to use non-invasive tool able to rule out CAD with 96% negative predictive value. This also translates into a potential to reduce onward patient referrals by ~50%. – a win-win for patients, payers and physicians.